Cambridge Healthtech Institute’s Second Annual

Combination Immunotherapy

Strategies and New Approaches for Better Results in the Clinic

20-21 March 2018 | Hilton London Canary Wharf | London

 

For successful Combination Immunotherapy, a better understanding is required of what is going on in the tumour, how the tumour antigens change, factors limiting the activity of T cells, and what the tumour is doing to provide an inhibitory environment.  The industry and academia are reaping the benefits of this knowledge and developing new combination approaches with new modes of action. In this track, attendees will discover how investigators are improving on the limitations of monotherapies with the application of clever combination strategies.

Preliminary Agenda


KEYNOTE

Temporal Programming of Synergistic Innate and Adaptive Immunotherapy of Cancer

K. Dane Wittrup, Ph.D., Carbon P. Dubbs Professor, Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology


COMBINING CHECKPOINT INHIBITORS WITH OTHER APPROACHES

Treg Depletion as Principal Substrate for Combination Cancer Immunotherapy

Sergio Quezada, Ph.D., Research, Haematology, UCL Cancer Institute


NOVEL APPROACHES

Novel Combination Approaches for Cancer Immunotherapy

Christian Klein, Ph.D., Distinguished Scientist, Head, Oncology Programs, Cancer Immunotherapy Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich

Promoting Host Anti-Tumor Immune Responses with Targeted Protein Therapeutics

Gregory P. Adams, Ph.D., CSO, Eleven Biotherapeutics

TCR-Engineered T Cells Combined with T Cell Co-Stimulation to Treat Solid Tumors

Reno Debets, Ph.D., Associate Professor, Tumor Immunology, Medical Oncology, Erasmus MC Cancer Institute

Hafnium Oxide Nanoparticles and Radiotherapy to Convert Immunologically “Cold” Tumor into “Hot” Tumor

Sébastien Paris, Ph.D., Head, Biology, Non-Clinical, Discovery, Nanobiotix

LAG-3: Identification & Validation of the Next Generation Checkpoint Pathway

Frederic Triebel, MD, Ph.D., CSO & CMO, Immutep S.A

Towards Targeting the Tie2–αvβ3 Integrin Axis as a Novel Therapy for Angiogenesis

Niv Papo, Ph.D., Group Leader, Biotechnology Engineering, Ben Gurion University of the Negev




For more details on the conference, please contact:
Nicole Lyscom, Ph.D.
Conference Director
Cambridge Healthtech Institute
+44 7791 866489
nlyscom@healthtech.com 

For sponsorship and exhibit information, please contact: 
Companies A-K
Jason Gerardi
Senior Manager, Business Development
+1 781-972-5452
jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Senior Manager, Business Development
Cambridge Healthtech Institute
+1 781-972-5471
dinerstein@healthtech.com